Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer
ACTO: A Phase II, Randomized, Placebo-Controlled Study Evaluating Olanzapine in the Management of Cancer Cachexia
Sponsor: National Cancer Institute (NCI)
Listed as NCT05705492, this PHASE2 trial focuses on Advanced Biliary Tract Carcinoma and Advanced Esophageal Carcinoma and remains actively recruiting participants. Sponsored by National Cancer Institute (NCI), it has been updated 11 times since 2024, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
-
May 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE2
-
Nov 2024 — Apr 2025 [monthly]
Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2
▶ Show 6 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Suspended → Recruiting
-
Dec 2023 — Jun 2024 [monthly]
Suspended PHASE2
-
Oct 2023 — Dec 2023 [monthly]
Suspended PHASE2
Status: Recruiting → Suspended
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Feb 2023 — Sep 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- OHSU Knight Cancer Institute
- Oregon Health and Science University
For direct contact, visit the study record on ClinicalTrials.gov .